PROMORE PHARMA

leading-edge medical innovation

Late stage development of two first-in-category wound care products

Stockholm, Aug 2020

Important Notice & Disclaimer

THIS PRESENTATION AND ANY OTHER INFORMATION DISCUSSED AT THE PRESENTATION (THE "PRESENTATION") IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION, WHICH HAS BEEN PREPARED AND IS ISSUED BY PROMORE PHARMA AB (THE "ISSUER") IS PRELIMINARY IN NATURE, BASED ON MANAGEMENT BELIEFS AND IS SUBJECT TO UPDATING, REVISION AND AMENDMENT. THIS PRESENTATION MAY NOT BE REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS.

This Presentation does not, and is not intended to, constitute or form part of, and should not be construed as, (i) any offer, solicitation or invitation to subscribe for, sell or issue, underwrite or otherwise acquire any shares, securities or financial instruments of the Issuer or its parent (the "Securities"), nor shall it, or the fact of its communication, form the basis of or be relied upon in connection with or act as any inducement to enter into any contract or commitment whatsoever with respect to any Securities; or (ii) any form of financial opinion, recommendation or investment advice with respect to any Securities. This Presentation is not a prospectus. Any decision to purchase Securities in the context of an offering should be made on the basis of information contained in the offering circular expected to be published by the Issuer in due course in relation to such an offering. The information and opinions contained in this Presentation are provided as at the date of the Presentation, are subject to change without notice and do not purport to contain all information that may be required to evaluate the Issuer. The information in this presentation is in draft form and has not been independently verified. Neither the Issuer, nor Redeye AB ("Financial adviser") or any of their respective partners, directors, officers, advisers, affiliates or representatives undertake or is under any duty to update this Presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information. None of the foregoing persons accept any responsibility whatsoever for the contents of this Presentation and no representation or warranty, express or implied, is made by any such person in relation to the contents of this Presentation, and no reliance should be placed on, fairness, accuracy or completeness of the information and opinions contained in this Presentation. The Issuer and the Financial adviser and their respective directors, officers, employees, partners, advisers and agents expressly disclaim, to the maximum extent permitted by law, any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in connection with the accuracy or completeness of the information or for any of the opinions contained herein, or any other written or oral information made available in connection with this Presentation, or for any errors, omissions or misstatements contained in this Presentation or such other information. None of the Issuer and Financial adviser or any of their respective directors, officers, employees, partners, advisers and agents shall have any liability whatsoever (in negligence or otherwise) for any direct, indirect or consequential loss, damages, costs or prejudices whatsoever arising from the use of this Presentation or its contents or otherwise arising in connection with this Presentation. The information contained in the Presentation does not constitute and may not be relied on in any manner as legal, tax, investment, accounting, regulatory or other advice on, about or in relation to the Issuer, nor does it constitute a recommendation regarding the Securities. You should seek independent and professional advice and conduct your own independent investigation and analysis of the information contained in this Presentation and of the business, operations, financial condition, prospects, status and affairs of the Issuer. This Presentation contains various forward-looking statements that reflect the Issuer's management's current views with respect to future events and anticipated financial and operational performance and include, among other things, changing economic, business or other market conditions, changing regulatory conditions and the prospects for growth. Forward-looking statements as a general matter are all statements other than statements as to historical facts or present facts or circumstances. The words "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions, identify certain of these forward-looking statements. Although Promore Pharma AB believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements. All statements (including forward looking statements) contained herein are made as of the date of this Presentation. The Issuer expressly undertakes no obligation to update or revise this Presentation in case such estimates, projections or forward-looking statements do not materialize or change in the future and the parties named above disclaim any such obligation to do so. Accordingly, prospective investors are cautioned not to place undue reliance on any of the forward-looking statements herein. Certain market and competitive position data contained in this Presentation has been obtained from published and non-published industry publications or reports conducted by third parties. Such publications or reports generally state that the information they contain has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. Neither the Issuer nor the Financial adviser have verified and can give no assurances as to the accuracy of such information, market data or other information contained in this Presentation that was extracted or derived from these publications and reports. Certain statements in this Presentation regarding the market and competitive position data are based on the internal analyses of the Issuer, which may involve certain assumptions and estimates based on the knowledge and experience of its management. Although the Issuer believes that its internal observations are reliable, its estimates are not reviewed or verified by any external sources. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation. The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Issuer does not intend to make any public offering of Securities in the United States. This presentation and its contents may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. In the United Kingdom, this Presentation is directed only at persons who are "Qualified Investors" within the meaning of meaning of Article 2(1)(e) of Directive 2003/71/EC, as amended (the "Prospectus Directive") (i) who have professional experience in matters relating to investments who fall within the definition of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); and/or (ii) fall within Article 49(2)(a) to (d) of the Order ("high net worth companies, unincorporated associations etc."); and/or (iii) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). In other member states of the European Economic Area, this Presentation is directed only at Qualified Investors. Any investment or investment activity to which this Presentation may relate would, if made available and engaged in, be made available only to and engaged in only with such persons. This Presentation must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the European Economic Area other than the United Kingdom, by persons who are not Qualified Investors. By attending a meeting where this Presentation is made, or by otherwise accessing the Presentation, you warrant, represent, undertake and acknowledge that: (i) you have read and agree to comply with the foregoing limitations and restrictions, (ii) you are able to receive this Presentation without contravention of any applicable legal and regulatory restrictions and you understand the sanctions attached to the misuse, disclosure or improper circulation of the Presentation, (iii) if you are in the European Economic Area, you are a Qualified Investor, and (iv) if you are in the United Kingdom, you are a Relevant Person.

Management Team

Jonas Ekblom, CEO

- Over 25 years of experience from the life science sector, with a focus in pharmacology and drug development.
- Experience from Bows Pharmaceuticals AG, Pharmacia, Biovitrum, Sequenom and Invitrogen (now Thermo Fischer)
- Ekblom has published over 60 peer-reviewed articles
- Joined 2010

Margit Mahlapuu, CSO

- Close to 20 years of experience in discovery and development of novel pharmaceuticals from the biotech and pharma industry.
- Experience from Arexis, AstraZeneca, Biovitrum
- Authored 50 articles in peer-reviewed scientific journals and inventor on 7 pending patent applications. Professor in Molecular Medicine at Sahlgrenska Academy
- Joined 2007

Erik Magnusson, CFO

- More than 35 years of experience from the financial markets and life sciences.
- Worked with banking, financial analysis, and as a corporate operations executive in biotech and retail
- Experience from Aros Securities, ABG Sundal Collier, Aleris Holding, Sentoclone, Systembolaget and Coop
- Joined 2020

PROMORE PHARMA
leading-edge medical innovation

Promore Pharma in Brief

Phase III – ensereptide

- Preventing adhesions after tendon repair surgery
- **No** prescription drugs
- **1 million** patients in EU, NA & JP
- Addressable **EU market 300 MUSD**
- Indication broadening opportunities

Phase IIb – ropocamptide

- Treating chronic wounds, mainly VLUs
- No prescription drugs
- 6 million patients in EU, NA & JP
- Addressable global market 3 BUSD
- Indication broadening opportunities

Vision: **To solve the global problems of scarring, adhesions and chronic wounds**

PROMORE PHARMA
leading-edge medical innovation

Local Delivery of Peptides: The Way to Go

Simple, reliable, and safe…

BIOAVAILABILITY
Drug available at site of action in a medically relevant amount

SAFETY
Rapid degradation of peptides in the bloodstream: very low systemic exposure

PROMORE PHARMA
leading-edge medical innovation

Ropocamptide (LL-37)

PROMORE PHARMA
leading-edge medical innovation

Venous Leg Ulcers (VLU)

- >15 million patients with **challenging wounds** on the major pharmaceutical markets: VLUs are the most prevalent category



- No prescription pharmaceuticals for VLU.
- Low R&D competition
- Costs for treating a VLU exceed 10,000 USD per episode

Current standard care is compression bandaging



Risk factors: obesity, smoking and sedentary lifestyle

PROMORE PHARMA
leading-edge medical innovation

Ropocamptide: Product Concept

About ropocamptide – the active ingredient

- Naturally occurring peptide (LL-37; cathelicidin)
  - Antimicrobial
  - Angiogenic
  - Stimulates keratinocyte migration
- LL-37 involved in wound biology
  - Present in acute wounds but not in chronic wounds

- Application frequency matches current medical standards
- Does not require change of medical practice
- Can be applied by patient or a nurse
- Excipients are well characterized and can be procured at a very low cost

A viscous hydrogel containing the peptide is applied 2-3 times weekly in conjunction with regular dressing changes

PROMORE PHARMA
leading-edge medical innovation

HEAL LL-37: Ongoing Phase IIb Trial in VLUs

Study basics

- Recruiting 120 patients (completing protocol) in 2 countries (Sweden, Poland)
- 3-week run-in on placebo; followed by treatment with active or placebo for 3 months (application 2 times per week); 4 months follow-up
- 3 arms with 40 subjects in each: 2 doses of ropocamptide vs. placebo



The subjects are randomized to three groups

- Placebo (N=40)
- ropocamptide 0.5 mg/mL (N=40)
- ropocamptide 1.6 mg/mL (N=40)

Criteria for evaluation

- % completely healed wounds
- Multiple secondary endpoints

Last-patient-last-dose in March 2020 - Readout expected in Q4/2020

PROMORE PHARMA
leading-edge medical innovation

Ropocamptide: Conclusion of Ongoing Phase IIb Trial



Last-patient-last-dose in March 2020 - Readout expected in Q4/2020

PROMORE PHARMA
leading-edge medical innovation

Ensereptide (PXL01)



PROMORE PHARMA
leading-edge medical innovation

Adhesions and Scars







Adhesions form after almost any type of surgery

PROMORE PHARMA
leading-edge medical innovation

Ensereptide: Product Concept

Single-injection of lubricating hyaluronate-based gel containing ensereptide

PRE-FILLED SYRINGES
Containing peptide solution and viscous carrier (HA), to be mixed at surgery

SAFETY
Rapid degradation of peptides in the bloodstream: very low systemic exposure



About ensereptide

- 25 aa peptide
- Derivative of naturally occurring human peptide (lactoferricin)
  - Unique anti-inflammatory action: prevents fibroblastic adhesions without interfering with wound healing
  - Pro-fibrinolytic properties
- Formulated in a viscous carrier

PROMORE PHARMA
leading-edge medical innovation

Phase III Study Planned in EU

Study Basics PHSU03

- ~600-700 patients with accidental transection of flexor tendon in zone II of the hand
- Single administration in conjunction with surgery of ensereptide (two doses) vs. placebo (saline) (1:1:1)
- Efficacy and safety followed until 12 months post-surgery
- Study centers in Sweden, Germany, Poland, Italy and India



Planned to initiate patient enrolment in H1 2021

PROMORE PHARMA
leading-edge medical innovation

PHSU03: Preparation Status

A Phase III clinical trial of ensereptide

- IB: complete
- CSP: complete and vetted with KOLs and CAs
- IMPD: in progress (est 90% completion)
- Clinical sites engaged
  - ✓ Sweden (4)
  - ✓ Poland (3)
  - ✓ Germany (3)
  - ✓ Italy (7)
  - ✓ India (10)
- Study organization aligned, including main CRO, CI, and subcontractors completed
- While awaiting financing, Promore Pharma is improving the supply chain for IMP

PROMORE PHARMA
leading-edge medical innovation

Corporate

PROMORE PHARMA
leading-edge medical innovation

Q2 2020 Financial Data

Operating Expenses



- EBIT was -6.7 MSEK in the second quarter 2020 (-7.4) and -14.0 MSEK (-12.9) in the first half 2020
  - Slightly decreasing R&D expenses in the quarter due to lower costs for HEAL LL-37 compared to 2019. For the first six months the situation was the opposite.
  - Decreasing external expenses both in the quarter and the first six months due to lower consultancy fees and lower traveling expenses
- Cash at 30 June 2020 was 39.9 MSEK

PROMORE PHARMA
leading-edge medical innovation

Promore Pharma and COVID-19

No major impact by the pandemic



Certain risks apply:

- Delayed interactions with authorities
- Limitations in our contacts with healthcare institutions
- Capacity limitations of subcontractors
- Changed priorities at other companies with potential interest in concluding license agreements and strategic alliances
- Uncertainties in the capital markets that may have implications for future capital raises

PROMORE PHARMA
leading-edge medical innovation

Concluding Remarks

1. Late stage clinical development phase
2. Unmet medical need – no pharmaceutical products
3. Validated technology with strong IP protection
4. Strong safety profile and low development costs
5. High growth potential
6. Low fixed costs and significant strategic partnerships in place

PROMORE PHARMA
leading-edge medical innovation

THANK YOU!

PROMORE PHARMA
leading-edge medical innovation